Frank Jozef Christiaan van Den Broek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Frank Jozef Christiaan van Den Broek has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Marcel G. W. Dijkgraaf
Department of Epidemiology and Data Science, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1100 DD Amsterdam, The Netherlands
7 shared publications - Jelle E. Bousema
Department of Surgery, Máxima MC, Veldhoven, Netherlands
5 shared publications - Louisa N. Spaans
Department of Surgery, Máxima Medical Center, Veldhoven, The Netherlands
5 shared publications Jouke T. Annema
Amsterdam UMC Location University of Amsterdam, Respiratory Medicine, Amsterdam, the Netherlands
4 shared publicationsMartijn van Dorp
Department of Cardiothoracic Surgery, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
4 shared publicationsAd F. T. M. Verhagen
Department of Cardio-Thoracic Surgery, Radboud University Medical Center, Nijmegen, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 5 May 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Postoperative pain management after VATS for spontaneous pneumothorax - a systematic review
Background: Historically, thoracic epidural analgesia has been the standard for postoperative pain management after surgery for spontaneous pneumothorax. With the advent of enhanced recovery after thoracic surgery protocols, less invasive locoregional analgesic techniques are increasingly considered. Due to lack of high-quality evidence, current guidelines do not address optimal analgesic strategies in this population. This systematic review evaluated the effectiveness of various analgesic techniques following video-assisted thoracoscopic surgery for spontaneous pneumothorax. Methods: Medline, Embase and Cochrane databases were searched until May 2025. Inclusion criteria were patients undergoing video-assisted thoracoscopic surgery for spontaneous pneumothorax, with clearly described postoperative analgesic management (e.g. epidural, locoregional, systemic) and pain scores (visual analgesic score or numeric pain rating score) within 48 h. The primary outcome was pain scores within 48 h postoperatively; secondary outcomes included adjunct analgesic use and complications. Risk of bias was assessed for the primary outcome. Results: Thirty studies comprising 3,203 patients were assessed: risk of bias was low in 3, moderate/some concerns in 24 and high in 3 studies. There were 10 comparative studies and 20 single-arm cohort studies applying solely systemic analgesia ( n = 14) or locoregional analgesia (n = 6). No single-arm cohort study applied solely epidural analgesia. Postoperative pain scores within 48 h were higher after systemic analgesia only, compared to the addition of locoregional or epidural analgesia. No clear differences were observed in analgesia-related complications between the analgesic techniques. Conclusions: Locoregional or epidural analgesia as part of a multimodal regimen was associated with the lowest postoperative pain scores, although differences were small. Substantial heterogeneity and low certainty of evidence precluded definitive recommendations. This review provides a foundation for future research investigating optimal analgesic strategies following surgery for spontaneous pneumothorax.
- 5 May 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Open AccessPostoperative pain management after VATS for spontaneous pneumothorax - a systematic review
Background: Historically, thoracic epidural analgesia has been the standard for postoperative pain management after surgery for spontaneous pneumothorax. With the advent of enhanced recovery after thoracic surgery protocols, less invasive locoregional analgesic techniques are increasingly considered. Due to lack of high-quality evidence, current guidelines do not address optimal analgesic strategies in this population. This systematic review evaluated the effectiveness of various analgesic techniques following video-assisted thoracoscopic surgery for spontaneous pneumothorax. Methods: Medline, Embase and Cochrane databases were searched until May 2025. Inclusion criteria were patients undergoing video-assisted thoracoscopic surgery for spontaneous pneumothorax, with clearly described postoperative analgesic management (e.g. epidural, locoregional, systemic) and pain scores (visual analgesic score or numeric pain rating score) within 48 h. The primary outcome was pain scores within 48 h postoperatively; secondary outcomes included adjunct analgesic use and complications. Risk of bias was assessed for the primary outcome. Results: Thirty studies comprising 3,203 patients were assessed: risk of bias was low in 3, moderate/some concerns in 24 and high in 3 studies. There were 10 comparative studies and 20 single-arm cohort studies applying solely systemic analgesia ( n = 14) or locoregional analgesia (n = 6). No single-arm cohort study applied solely epidural analgesia. Postoperative pain scores within 48 h were higher after systemic analgesia only, compared to the addition of locoregional or epidural analgesia. No clear differences were observed in analgesia-related complications between the analgesic techniques. Conclusions: Locoregional or epidural analgesia as part of a multimodal regimen was associated with the lowest postoperative pain scores, although differences were small. Substantial heterogeneity and low certainty of evidence precluded definitive recommendations. This review provides a foundation for future research investigating optimal analgesic strategies following surgery for spontaneous pneumothorax.
- Open Access
- 26 March 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68 (4)
Progressive Versus Conservative Chest Tube Management Following Surgery for Primary Spontaneous Pneumothorax
Objectives: “Enhanced recovery after thoracic surgery” is increasingly implemented following surgery for primary spontaneous pneumothorax (PSP). Historically, postoperative chest tubes are left in place for several days to ensure adequate pleurodesis and prevent recurrence. Prompt chest tube removal upon cessation of air leakage may enhance recovery but potentially increases risk of recurrence. We evaluated progressive chest tube management following surgical pleurodesis for PSP. Methods: Retrospective multicentre study of patients undergoing surgical pleurodesis for PSP between 2020 and 2023. Hospitals with implemented progressive chest tube management (removal upon cessation of air leakage <8 hours) were compared against hospitals with conservative management (removal after 1-2 days). Outcome measures, corrected for bias using directed acyclic graphs, were postoperative length of stay (LOS), chest tube duration, complications, and ipsilateral recurrences. Results: A total of 183 patients from 5 hospitals were included: 99 patients in the progressive and 84 in the conservative group. Follow-up and baseline characteristics were comparable, except for surgical indication, pleurodesis technique, and use of postoperative chest X-ray. Progressive management significantly reduced LOS (Δ1 day), chest tube duration (Δ2 days), and complications (9.1 vs 21.4%). After correction for pleurodesis technique, persistent air leakage, and chest X-ray, LOS was reduced by 1.03 day (P < .001). Recurrences (6.6%) were similar across groups (P = .388). Conclusions: Progressive chest tube management reduces LOS, chest tube duration, and complications without increasing the risk of recurrence in this retrospective comparative study. A prospective study is necessary to validate these findings before considering widespread implementation.
- 26 March 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68 (4)
Open AccessProgressive Versus Conservative Chest Tube Management Following Surgery for Primary Spontaneous Pneumothorax
Objectives: “Enhanced recovery after thoracic surgery” is increasingly implemented following surgery for primary spontaneous pneumothorax (PSP). Historically, postoperative chest tubes are left in place for several days to ensure adequate pleurodesis and prevent recurrence. Prompt chest tube removal upon cessation of air leakage may enhance recovery but potentially increases risk of recurrence. We evaluated progressive chest tube management following surgical pleurodesis for PSP. Methods: Retrospective multicentre study of patients undergoing surgical pleurodesis for PSP between 2020 and 2023. Hospitals with implemented progressive chest tube management (removal upon cessation of air leakage <8 hours) were compared against hospitals with conservative management (removal after 1-2 days). Outcome measures, corrected for bias using directed acyclic graphs, were postoperative length of stay (LOS), chest tube duration, complications, and ipsilateral recurrences. Results: A total of 183 patients from 5 hospitals were included: 99 patients in the progressive and 84 in the conservative group. Follow-up and baseline characteristics were comparable, except for surgical indication, pleurodesis technique, and use of postoperative chest X-ray. Progressive management significantly reduced LOS (Δ1 day), chest tube duration (Δ2 days), and complications (9.1 vs 21.4%). After correction for pleurodesis technique, persistent air leakage, and chest X-ray, LOS was reduced by 1.03 day (P < .001). Recurrences (6.6%) were similar across groups (P = .388). Conclusions: Progressive chest tube management reduces LOS, chest tube duration, and complications without increasing the risk of recurrence in this retrospective comparative study. A prospective study is necessary to validate these findings before considering widespread implementation.
- Open Access
- 17 November 2025
- Published by Springer Nature in BMC Anesthesiology
- Vol. 25 (1) , 567
Patient preferences for analgesia in lung surgery: an observational cohort study
Background: Optimal analgesia following thoracoscopic lung surgery is crucial for patient comfort and effective recovery. Despite the lack of high quality evidence in guidelines, experts favour locoregional analgesic techniques above thoracic epidural analgesia (TEA), without considering patient preferences. This study investigates patient choices to aid in shared-decision making and incorporation in guidelines. Methods: Through adaptive conjoint analysis (ACA) concerning attributes (characteristics) related to analgesic techniques and treatment trade-off methods (TTM) comparing scenarios with locoregional analgesia against TEA, 200 patients planned for thoracoscopic lung resection in five Dutch hospitals received online questionnaires. In the TTM, patients were repeatedly asked to choose between two scenarios: one describing thoracic epidural analgesia with fixed low levels of pain and the other representing locoregional analgesia with varying pain levels, to assess trade-off thresholds. For the ACA, Relative Importance (RI) of the characteristics was calculated with 95%-confidence intervals (CI). Results: Response rates of ACA and TTM questionnaires were 72% (144/200) and 71% (141/200) respectively. The most important characteristics were state of consciousness (‘awake or under general anaesthesia’) while receiving the analgesic technique (RI 20.45; 95%-CI 19.12–21.75) and mobilisation (RI 19.42; 95%-CI 18.45–20.38). In the TTM, 10 patients (7.1%) consistently chose the TEA scenario, irrespective of the benefits of locoregional analgesia. In contrast, 131 patients (92.9%) preferred experiencing more moments of pain as trade-off for the potential advantages associated with locoregional analgesia. Conclusion: Regarding analgesia following thoracoscopic lung surgery, patients considered the state of consciousness while receiving the analgesic technique (awake or under general anaesthesia) and postoperative mobility as the most important characteristics. Over 92% of patients are willing to accept more moments of pain as trade-off for the potential benefits of locoregional analgesia. These findings are aligned with current guideline recommendations and support the inclusion of patient preferences in shared decision-making.
- 17 November 2025
- Published by Springer Nature in BMC Anesthesiology
- Vol. 25 (1) , 567
Open AccessPatient preferences for analgesia in lung surgery: an observational cohort study
Background: Optimal analgesia following thoracoscopic lung surgery is crucial for patient comfort and effective recovery. Despite the lack of high quality evidence in guidelines, experts favour locoregional analgesic techniques above thoracic epidural analgesia (TEA), without considering patient preferences. This study investigates patient choices to aid in shared-decision making and incorporation in guidelines. Methods: Through adaptive conjoint analysis (ACA) concerning attributes (characteristics) related to analgesic techniques and treatment trade-off methods (TTM) comparing scenarios with locoregional analgesia against TEA, 200 patients planned for thoracoscopic lung resection in five Dutch hospitals received online questionnaires. In the TTM, patients were repeatedly asked to choose between two scenarios: one describing thoracic epidural analgesia with fixed low levels of pain and the other representing locoregional analgesia with varying pain levels, to assess trade-off thresholds. For the ACA, Relative Importance (RI) of the characteristics was calculated with 95%-confidence intervals (CI). Results: Response rates of ACA and TTM questionnaires were 72% (144/200) and 71% (141/200) respectively. The most important characteristics were state of consciousness (‘awake or under general anaesthesia’) while receiving the analgesic technique (RI 20.45; 95%-CI 19.12–21.75) and mobilisation (RI 19.42; 95%-CI 18.45–20.38). In the TTM, 10 patients (7.1%) consistently chose the TEA scenario, irrespective of the benefits of locoregional analgesia. In contrast, 131 patients (92.9%) preferred experiencing more moments of pain as trade-off for the potential advantages associated with locoregional analgesia. Conclusion: Regarding analgesia following thoracoscopic lung surgery, patients considered the state of consciousness while receiving the analgesic technique (awake or under general anaesthesia) and postoperative mobility as the most important characteristics. Over 92% of patients are willing to accept more moments of pain as trade-off for the potential benefits of locoregional analgesia. These findings are aligned with current guideline recommendations and support the inclusion of patient preferences in shared decision-making.
- Top Cited Papers
- 1 August 2025
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 160 (8) , 855-864
Intercostal or Paravertebral Block vs Thoracic Epidural in Lung Surgery
Importance: Effective pain control after thoracic surgery is crucial for enhanced recovery. While thoracic epidural analgesia (TEA) traditionally ensures optimal analgesia, its adverse effects conflict with the principles of enhanced recovery after thoracic surgery. High-quality randomized data regarding less invasive alternative locoregional techniques are lacking.Objective: To evaluate the efficacy of continuous paravertebral block (PVB) and a single-shot intercostal nerve block (ICNB) as alternatives to TEA.Design, Setting, and Participants: This randomized clinical trial compared PVB and ICNB vs TEA (1:1:1) in patients undergoing thoracoscopic anatomical lung resection at 11 hospitals in the Netherlands and Belgium, enrolled from March 5, 2021, to September 5, 2023. The study used a noninferiority design for pain and a superiority design for quality of recovery (QoR).Interventions: Continuous PVB and single-shot ICNB.Main Outcomes and Measures: Primary outcomes were pain, defined as mean proportion of pain scores 4 or greater during postoperative days (POD) 0 through 2 (noninferiority margin for the upper limit [UL] 1-sided 98.65% CI, 17.5%), and QoR, assessed with the QoR-15 questionnaire at POD 1 and 2. Secondary measures included opioid consumption, mobilization, complications, and hospitalization.Results: A total of 450 patients were randomized, with 389 included in the intention-to-treat (ITT) analysis (mean [SD] age, 66 [9] years; 208 female patients [54%] and 181 male [46%]). Of these 389 patients, 131 received TEA, 134 received PVB, and 124 received ICNB. The mean proportions of pain scores 4 or greater were 20.7% (95% CI, 16.5%-24.9%) for TEA, 35.5% (95% CI, 30.1%-40.8%) for PVB, and 29.5% (95% CI, 24.6%-34.4%) for ICNB. While PVB was inferior to TEA regarding pain (ITT: UL, 22.4%; analysis per-protocol [PP]: UL, 23.1%), ICNB was noninferior to TEA (ITT: UL, 16.1%; PP: UL, 17.0%). The mean (SD) QoR-15 scores were similar across groups: 104.96 (20.47) for TEA, 106.06 (17.94; P = .641) for PVB (P = .64 for that comparison), and 106.85 (21.11) for ICNB (P = .47 for that comparison). Both ICNB and PVB significantly reduced opioid consumption and enhanced mobility compared with TEA, with no significant differences in complications. Hospitalization was shorter in the ICNB group.Conclusions and Relevance: After thoracoscopic anatomical lung resection, only ICNB provides noninferior pain relief compared with TEA. ICNB emerges as an alternative to TEA, although risks and benefits should be weighed for optimal personalized pain control.Trial Registration: ClinicalTrials.gov Identifier: NCT05491239
- 1 August 2025
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 160 (8) , 855-864
Top Cited PapersIntercostal or Paravertebral Block vs Thoracic Epidural in Lung Surgery
Importance: Effective pain control after thoracic surgery is crucial for enhanced recovery. While thoracic epidural analgesia (TEA) traditionally ensures optimal analgesia, its adverse effects conflict with the principles of enhanced recovery after thoracic surgery. High-quality randomized data regarding less invasive alternative locoregional techniques are lacking.Objective: To evaluate the efficacy of continuous paravertebral block (PVB) and a single-shot intercostal nerve block (ICNB) as alternatives to TEA.Design, Setting, and Participants: This randomized clinical trial compared PVB and ICNB vs TEA (1:1:1) in patients undergoing thoracoscopic anatomical lung resection at 11 hospitals in the Netherlands and Belgium, enrolled from March 5, 2021, to September 5, 2023. The study used a noninferiority design for pain and a superiority design for quality of recovery (QoR).Interventions: Continuous PVB and single-shot ICNB.Main Outcomes and Measures: Primary outcomes were pain, defined as mean proportion of pain scores 4 or greater during postoperative days (POD) 0 through 2 (noninferiority margin for the upper limit [UL] 1-sided 98.65% CI, 17.5%), and QoR, assessed with the QoR-15 questionnaire at POD 1 and 2. Secondary measures included opioid consumption, mobilization, complications, and hospitalization.Results: A total of 450 patients were randomized, with 389 included in the intention-to-treat (ITT) analysis (mean [SD] age, 66 [9] years; 208 female patients [54%] and 181 male [46%]). Of these 389 patients, 131 received TEA, 134 received PVB, and 124 received ICNB. The mean proportions of pain scores 4 or greater were 20.7% (95% CI, 16.5%-24.9%) for TEA, 35.5% (95% CI, 30.1%-40.8%) for PVB, and 29.5% (95% CI, 24.6%-34.4%) for ICNB. While PVB was inferior to TEA regarding pain (ITT: UL, 22.4%; analysis per-protocol [PP]: UL, 23.1%), ICNB was noninferior to TEA (ITT: UL, 16.1%; PP: UL, 17.0%). The mean (SD) QoR-15 scores were similar across groups: 104.96 (20.47) for TEA, 106.06 (17.94; P = .641) for PVB (P = .64 for that comparison), and 106.85 (21.11) for ICNB (P = .47 for that comparison). Both ICNB and PVB significantly reduced opioid consumption and enhanced mobility compared with TEA, with no significant differences in complications. Hospitalization was shorter in the ICNB group.Conclusions and Relevance: After thoracoscopic anatomical lung resection, only ICNB provides noninferior pain relief compared with TEA. ICNB emerges as an alternative to TEA, although risks and benefits should be weighed for optimal personalized pain control.Trial Registration: ClinicalTrials.gov Identifier: NCT05491239
- Open Access
- 1 April 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (4) , 2194-2205
Early versus late chest tube removal after surgery for primary spontaneous pneumothorax—a systematic review and meta-analysis
Background: The optimal timing of postoperative chest tube removal remains disputable. Traditionally, chest tubes are left in place for several days for adequate pleurodesis and recurrence prevention after surgery for primary spontaneous pneumothorax (PSP). Currently, early tube removal, defined as immediate removal upon cessation of air leakage, is increasingly practiced. This study aimed to evaluate the safety of early chest tube removal in terms of recurrence in these patients. Methods: MEDLINE (PubMed), EMBASE and Cochrane databases were searched until January 2024. Inclusion criteria encompassed patients undergoing pleurodesis through video-assisted thoracoscopic surgery (VATS) for PSP if chest tube management was clearly described to discriminate between early and late tube removal protocols, and recurrence rate with a postoperative follow-up period of at least six months was reported. The primary outcome was recurrence rate, with secondary outcomes including postoperative length of stay (LOS), prolonged air leakage (PAL) and chest tube duration. Subgroup analysis contained type of pleurodesis. The quality of evidence was evaluated with the Grading of Recommendations Assessment, Development and Evaluation method. Results: Thirty-six studies comprising 6,166 patients were included, lacking direct comparative studies on early versus late chest tube removal. Due to loss to follow-up, 6,063 patients were analysed regarding recurrence rate, resulting in 4.49% [95% confidence interval (CI): 3.33–6.03%; I2=65.6%] after late removal and 7.61% (95% CI: 5.44–10.57%; I2=8.2%) after early removal (P=0.02). Among the secondary outcomes only chest tube duration was significantly different between early and late removal [2.50 (95% CI: 2.31–2.71) versus 3.42 (95% CI: 3.08–3.81) days, PConclusions: Although no direct comparative studies were retrieved, the best available evidence suggests that early chest tube removal may be associated with a slightly higher recurrence rate after surgical pleurodesis for pneumothorax. High-quality evidence is needed before implementing early removal.
- 1 April 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (4) , 2194-2205
Open AccessEarly versus late chest tube removal after surgery for primary spontaneous pneumothorax—a systematic review and meta-analysis
Background: The optimal timing of postoperative chest tube removal remains disputable. Traditionally, chest tubes are left in place for several days for adequate pleurodesis and recurrence prevention after surgery for primary spontaneous pneumothorax (PSP). Currently, early tube removal, defined as immediate removal upon cessation of air leakage, is increasingly practiced. This study aimed to evaluate the safety of early chest tube removal in terms of recurrence in these patients. Methods: MEDLINE (PubMed), EMBASE and Cochrane databases were searched until January 2024. Inclusion criteria encompassed patients undergoing pleurodesis through video-assisted thoracoscopic surgery (VATS) for PSP if chest tube management was clearly described to discriminate between early and late tube removal protocols, and recurrence rate with a postoperative follow-up period of at least six months was reported. The primary outcome was recurrence rate, with secondary outcomes including postoperative length of stay (LOS), prolonged air leakage (PAL) and chest tube duration. Subgroup analysis contained type of pleurodesis. The quality of evidence was evaluated with the Grading of Recommendations Assessment, Development and Evaluation method. Results: Thirty-six studies comprising 6,166 patients were included, lacking direct comparative studies on early versus late chest tube removal. Due to loss to follow-up, 6,063 patients were analysed regarding recurrence rate, resulting in 4.49% [95% confidence interval (CI): 3.33–6.03%; I2=65.6%] after late removal and 7.61% (95% CI: 5.44–10.57%; I2=8.2%) after early removal (P=0.02). Among the secondary outcomes only chest tube duration was significantly different between early and late removal [2.50 (95% CI: 2.31–2.71) versus 3.42 (95% CI: 3.08–3.81) days, PConclusions: Although no direct comparative studies were retrieved, the best available evidence suggests that early chest tube removal may be associated with a slightly higher recurrence rate after surgical pleurodesis for pneumothorax. High-quality evidence is needed before implementing early removal.
- Open Access
- 22 March 2025
- Published by Elsevier in Lung Cancer
- Vol. 202, 108462
Two-year survival and disease recurrence after endosonography with or without confirmatory mediastinoscopy for resectable lung cancer (a short communication of the MEDIASTrial follow-up)
- 22 March 2025
- Published by Elsevier in Lung Cancer
- Vol. 202, 108462
Open AccessTwo-year survival and disease recurrence after endosonography with or without confirmatory mediastinoscopy for resectable lung cancer (a short communication of the MEDIASTrial follow-up)
- Open Access
- 1 October 2024
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 16 (10) , 6553-6564
Incidence of early persistent pain after video-assisted thoracoscopic surgery: a single-centre prospective cohort study
Background: Despite the benefits of video-assisted thoracoscopic surgery (VATS), postoperative acute pain and nerve injury are still present and contribute to early persistent and chronic pain. The purpose of this study is to describe the incidence of early persistent pain (EPP) after VATS, which remains unexplored, to enhance patient care and promote awareness among clinicians regarding this clinical condition. Methods: A single-center prospective cohort study that included consecutive patients undergoing VATS between January 2021 and March 2023. The primary outcome was the incidence of EPP, defined as pain experienced at 3 to 4 weeks follow-up. Secondary outcomes were risk factors associated with EPP, characteristics during physical examination, acute postoperative pain scores, the use of additional analgesia and complications between patients with and without EPP. Results: Of 117 patients, 16.2% [95% confidence interval (CI): 9–23%] developed EPP. The presence of acute postoperative pain was the only risk factor for EPP. The pain was mostly localized at the utility and ventral incision. Hyperesthesia, hypoesthesia and a positive pinch test were the most common sensory disturbances. Patients with EPP showed significantly higher acute pain scores until postoperative day (POD) 4, more frequently used additional opioids until POD 2, and had comparable complications. Conclusions: Early persistent postoperative pain is present in 16.2% of patients after VATS. Acute postoperative pain is the strongest risk factor for developing such persistent pain. This underlines that awareness of clinicians for strategies that optimize postoperative pain management is of utmost importance.
- 1 October 2024
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 16 (10) , 6553-6564
Open AccessIncidence of early persistent pain after video-assisted thoracoscopic surgery: a single-centre prospective cohort study
Background: Despite the benefits of video-assisted thoracoscopic surgery (VATS), postoperative acute pain and nerve injury are still present and contribute to early persistent and chronic pain. The purpose of this study is to describe the incidence of early persistent pain (EPP) after VATS, which remains unexplored, to enhance patient care and promote awareness among clinicians regarding this clinical condition. Methods: A single-center prospective cohort study that included consecutive patients undergoing VATS between January 2021 and March 2023. The primary outcome was the incidence of EPP, defined as pain experienced at 3 to 4 weeks follow-up. Secondary outcomes were risk factors associated with EPP, characteristics during physical examination, acute postoperative pain scores, the use of additional analgesia and complications between patients with and without EPP. Results: Of 117 patients, 16.2% [95% confidence interval (CI): 9–23%] developed EPP. The presence of acute postoperative pain was the only risk factor for EPP. The pain was mostly localized at the utility and ventral incision. Hyperesthesia, hypoesthesia and a positive pinch test were the most common sensory disturbances. Patients with EPP showed significantly higher acute pain scores until postoperative day (POD) 4, more frequently used additional opioids until POD 2, and had comparable complications. Conclusions: Early persistent postoperative pain is present in 16.2% of patients after VATS. Acute postoperative pain is the strongest risk factor for developing such persistent pain. This underlines that awareness of clinicians for strategies that optimize postoperative pain management is of utmost importance.
- Open Access
- 1 November 2023
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 37 (5)
Pain management after pneumothorax surgery: intercostal nerve block or thoracic epidural analgesia
In patients undergoing video-assisted thoracoscopic surgery for pneumothorax, the benefits and risks of single-shot intercostal nerve block as loco-regional analgesia are not well known. We retrospectively compared the effectiveness of intercostal nerve blocks as a viable alternative to thoracic epidural analgesia (TEA) regarding pain control and enhanced recovery. A retrospective multicentre analysis with single-centre propensity score matching was performed in patients undergoing video-assisted thoracoscopic surgery for pneumothorax receiving either TEA or intercostal nerve block. The primary outcome was a proportion of pain scores ≥4 (scale 0–10) until postoperative day (POD) 3. Secondary outcomes included variation in pain over time, additional opioid use, length of stay, mobility, complications and recurrence rate. In 218 patients, TEA was compared to intercostal nerve block and showed no difference in the proportion of pain scores ≥4 {14.3% [interquartile range (IQR) 0.0–33.3] vs 11.1% (IQR 0.0–27.3) respectively, P = 0.24}, more frequently needed additional opioids on the day of surgery (18% vs 48%) and first POD (20% vs 42%), had a shorter length of stay (4.0 days [IQR 3.0–7.0] vs 3.0 days [IQR 2.8–4.0]) and were significantly more mobile until POD 3, while having similar recurrences. Intercostal nerve block had higher pain scores early in the course whereas TEA had higher late (rebound) pain scores. In a multimodal analgesic setting with additional opioids, intercostal nerve block shows comparable moments of unacceptable pain from POD 0–3 compared to TEA and is linked to improved mobility. Results require randomized confirmation.
- 1 November 2023
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 37 (5)
Open AccessPain management after pneumothorax surgery: intercostal nerve block or thoracic epidural analgesia
In patients undergoing video-assisted thoracoscopic surgery for pneumothorax, the benefits and risks of single-shot intercostal nerve block as loco-regional analgesia are not well known. We retrospectively compared the effectiveness of intercostal nerve blocks as a viable alternative to thoracic epidural analgesia (TEA) regarding pain control and enhanced recovery. A retrospective multicentre analysis with single-centre propensity score matching was performed in patients undergoing video-assisted thoracoscopic surgery for pneumothorax receiving either TEA or intercostal nerve block. The primary outcome was a proportion of pain scores ≥4 (scale 0–10) until postoperative day (POD) 3. Secondary outcomes included variation in pain over time, additional opioid use, length of stay, mobility, complications and recurrence rate. In 218 patients, TEA was compared to intercostal nerve block and showed no difference in the proportion of pain scores ≥4 {14.3% [interquartile range (IQR) 0.0–33.3] vs 11.1% (IQR 0.0–27.3) respectively, P = 0.24}, more frequently needed additional opioids on the day of surgery (18% vs 48%) and first POD (20% vs 42%), had a shorter length of stay (4.0 days [IQR 3.0–7.0] vs 3.0 days [IQR 2.8–4.0]) and were significantly more mobile until POD 3, while having similar recurrences. Intercostal nerve block had higher pain scores early in the course whereas TEA had higher late (rebound) pain scores. In a multimodal analgesic setting with additional opioids, intercostal nerve block shows comparable moments of unacceptable pain from POD 0–3 compared to TEA and is linked to improved mobility. Results require randomized confirmation.
- Open Access
Colorectal Pulmonary Metastases: Pulmonary Metastasectomy or Stereotactic Radiotherapy?
Background: Pulmonary metastasectomy and stereotactic ablative radiotherapy (SABR) are both guideline-recommended treatments for selected patients with oligometastatic colorectal pulmonary metastases. However, there is limited evidence comparing these local treatment modalities in similar patient groups. Methods: We retrospectively reviewed records of consecutive patients treated for colorectal pulmonary metastases with surgical metastasectomy or SABR from 2012 to 2019 at two Dutch referral hospitals that had different approaches toward the local treatment of colorectal pulmonary metastases, one preferring surgery, the other preferring SABR. Two comparable patient groups were identified based on tumor and treatment characteristics. Results: The metastasectomy group comprised 40 patients treated for 69 metastases, and the SABR group had 60 patients who were treated for 90 metastases. Median follow-up was 38 months (IQR: 26–67) in the surgery group and 46 months (IQR: 30–79) in the SABR group. Median OS was 58 months (CI: 20–94) in the metastasectomy group and 70 months (CI: 29–111) in the SABR group (p = 0.23). Five-year local recurrence-free survival (LRFS) was 44% after metastasectomy and 30% after SABR (p = 0.16). Median progression-free survival (PFS) was 15 months (CI: 3–26) in the metastasectomy group and 10 months (CI: 6–13) in the SABR group (p = 0.049). Local recurrence rate was 12.5/7.2% of patients/metastases respectively after metastasectomy and 38.3/31.1% after SABR (p < 0.001). Lower BED Gy10 was correlated with an increased likelihood of recurrence (p = 0.025). Clavien Dindo grade III-V complication rates were 2.5% after metastasectomy and 0% after SABR (p = 0.22). Conclusion: In this retrospective cohort study, pulmonary metastasectomy and SABR had comparable overall survival, local recurrence-free survival, and complication rates, despite patients in the SABR group having a significantly lower progression-free survival and local control rate. These data would support a randomized controlled trial comparing surgery and SABR in operable patients with radically resectable colorectal pulmonary metastases.
Open AccessColorectal Pulmonary Metastases: Pulmonary Metastasectomy or Stereotactic Radiotherapy?
Background: Pulmonary metastasectomy and stereotactic ablative radiotherapy (SABR) are both guideline-recommended treatments for selected patients with oligometastatic colorectal pulmonary metastases. However, there is limited evidence comparing these local treatment modalities in similar patient groups. Methods: We retrospectively reviewed records of consecutive patients treated for colorectal pulmonary metastases with surgical metastasectomy or SABR from 2012 to 2019 at two Dutch referral hospitals that had different approaches toward the local treatment of colorectal pulmonary metastases, one preferring surgery, the other preferring SABR. Two comparable patient groups were identified based on tumor and treatment characteristics. Results: The metastasectomy group comprised 40 patients treated for 69 metastases, and the SABR group had 60 patients who were treated for 90 metastases. Median follow-up was 38 months (IQR: 26–67) in the surgery group and 46 months (IQR: 30–79) in the SABR group. Median OS was 58 months (CI: 20–94) in the metastasectomy group and 70 months (CI: 29–111) in the SABR group (p = 0.23). Five-year local recurrence-free survival (LRFS) was 44% after metastasectomy and 30% after SABR (p = 0.16). Median progression-free survival (PFS) was 15 months (CI: 3–26) in the metastasectomy group and 10 months (CI: 6–13) in the SABR group (p = 0.049). Local recurrence rate was 12.5/7.2% of patients/metastases respectively after metastasectomy and 38.3/31.1% after SABR (p < 0.001). Lower BED Gy10 was correlated with an increased likelihood of recurrence (p = 0.025). Clavien Dindo grade III-V complication rates were 2.5% after metastasectomy and 0% after SABR (p = 0.22). Conclusion: In this retrospective cohort study, pulmonary metastasectomy and SABR had comparable overall survival, local recurrence-free survival, and complication rates, despite patients in the SABR group having a significantly lower progression-free survival and local control rate. These data would support a randomized controlled trial comparing surgery and SABR in operable patients with radically resectable colorectal pulmonary metastases.
- Open Access
- 5 April 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (22) , 3805-+
Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial
PURPOSE: Resectable non–small-cell lung cancer (NSCLC) with a high probability of mediastinal nodal involvement requires mediastinal staging by endosonography and, in the absence of nodal metastases, confirmatory mediastinoscopy according to current guidelines. However, randomized data regarding immediate lung tumor resection after systematic endosonography versus additional confirmatory mediastinoscopy before resection are lacking. METHODS: Patients with (suspected) resectable NSCLC and an indication for mediastinal staging after negative systematic endosonography were randomly assigned to immediate lung tumor resection or confirmatory mediastinoscopy followed by tumor resection. The primary outcome in this noninferiority trial (noninferiority margin of 8% that previously showed to not compromise survival, Pnoninferior < .0250) was the presence of unforeseen N2 disease after tumor resection with lymph node dissection. Secondary outcomes were 30-day major morbidity and mortality. RESULTS: Between July 17, 2017, and October 5, 2020, 360 patients were randomly assigned, 178 to immediate lung tumor resection (seven dropouts) and 182 to confirmatory mediastinoscopy first (seven dropouts before and six after mediastinoscopy). Mediastinoscopy detected metastases in 8.0% (14/175; 95% CI, 4.8 to 13.0) of patients. Unforeseen N2 rate after immediate resection (8.8%) was noninferior compared with mediastinoscopy first (7.7%) in both intention-to-treat (Δ, 1.03%; UL 95% CIΔ, 7.2%; Pnoninferior = .0144) and per-protocol analyses (Δ, 0.83%; UL 95% CIΔ, 7.3%; Pnoninferior = .0157). Major morbidity and 30-day mortality was 12.9% after immediate resection versus 15.4% after mediastinoscopy first ( P = .4940). CONCLUSION: On the basis of our chosen noninferiority margin in the rate of unforeseen N2, confirmatory mediastinoscopy after negative systematic endosonography can be omitted in patients with resectable NSCLC and an indication for mediastinal staging.
- 5 April 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (22) , 3805-+
Open AccessEndosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial
PURPOSE: Resectable non–small-cell lung cancer (NSCLC) with a high probability of mediastinal nodal involvement requires mediastinal staging by endosonography and, in the absence of nodal metastases, confirmatory mediastinoscopy according to current guidelines. However, randomized data regarding immediate lung tumor resection after systematic endosonography versus additional confirmatory mediastinoscopy before resection are lacking. METHODS: Patients with (suspected) resectable NSCLC and an indication for mediastinal staging after negative systematic endosonography were randomly assigned to immediate lung tumor resection or confirmatory mediastinoscopy followed by tumor resection. The primary outcome in this noninferiority trial (noninferiority margin of 8% that previously showed to not compromise survival, Pnoninferior < .0250) was the presence of unforeseen N2 disease after tumor resection with lymph node dissection. Secondary outcomes were 30-day major morbidity and mortality. RESULTS: Between July 17, 2017, and October 5, 2020, 360 patients were randomly assigned, 178 to immediate lung tumor resection (seven dropouts) and 182 to confirmatory mediastinoscopy first (seven dropouts before and six after mediastinoscopy). Mediastinoscopy detected metastases in 8.0% (14/175; 95% CI, 4.8 to 13.0) of patients. Unforeseen N2 rate after immediate resection (8.8%) was noninferior compared with mediastinoscopy first (7.7%) in both intention-to-treat (Δ, 1.03%; UL 95% CIΔ, 7.2%; Pnoninferior = .0144) and per-protocol analyses (Δ, 0.83%; UL 95% CIΔ, 7.3%; Pnoninferior = .0157). Major morbidity and 30-day mortality was 12.9% after immediate resection versus 15.4% after mediastinoscopy first ( P = .4940). CONCLUSION: On the basis of our chosen noninferiority margin in the rate of unforeseen N2, confirmatory mediastinoscopy after negative systematic endosonography can be omitted in patients with resectable NSCLC and an indication for mediastinal staging.